Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Recruiting · Phase 1, Phase 2 · NCT03761108
Conditions: Multiple Myeloma
At a glance
- Research payments reported, 2025
- $2.7M
- U.S. investigators named
- 16
- Sites paid
- 14
- Planned or actual enrollment
- 387
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- Linvoseltamab (drug)
- Dates
- Started 2019-01-23; completion 2033-06-16
- Results posted
- Not yet
The main purpose of this study is to learn about the safety of linvoseltamab and to find out what is the best dose of linvoseltamab to give to patients with multiple myeloma and to look for any signs that linvoseltamab can effectively treat cancer. The study is looking at several other research questions, including: * Side effects that may be experienced by people receiving linvoseltamab * How linvoseltamab works in the body * How much linvoseltamab is present in the blood * How linvoseltamab may work to treat cancer
From ClinicalTrials.gov, last updated 2026-10-26. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $2.7M in research payments for this study in 2025 (626 payments).
Products named: Lynozyfic
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Rachid C. Baz, MD Hematology & Oncology · Tampa, FL
- James E. Hoffman, M.D. Hematology & Oncology · Miami, FL
- Nisha S. Joseph, M.D. Medical Oncology · Atlanta, GA
- Attaya Suvannasankha, M.D. Hematology & Oncology · Indianapolis, IN
- Joseph J. Maly, M.D. Hematology & Oncology · Louisville, KY
- Matthew J. Pianko, M.D. Hematology · Ann Arbor, MI
- Jeffrey A. Zonder, MD Hematology & Oncology · Detroit, MI
- Mansi R. Shah, M.D. Hematology · New Brunswick, NJ
- Divaya Bhutani, MD Hematology · New York, NY
- Joshua R. Richter, M.D. Medical Oncology · New York, NY
- Naresh Bumma, M.D. Hematology · Columbus, OH
- Rebecca W. Silbermann, MD Hematology · Portland, OR
- Hans Lee, M.D. Hematology & Oncology · Nashville, TN
- Madhav V. Dhodapkar, MD Hematology & Oncology · Seattle, WA
- Swathi Namburi, MD Hematology & Oncology · Seattle, WA
- Christine Ye Physical Therapy Assistant · Vancouver, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- The Ohio State University $391,643
- Swedish Medical Center, WA $372,274
- Ut MD Anderson Cancer Center $283,837
- Icahn School of Medicine at Mount Sinai $265,796
- Indiana University $248,208
- Moffitt Cancer Center $175,178
- University of Michigan Health System, MI $170,409
- $162,779
- Norton Healthcare Inc $125,440
- The Trustees of Columbia University in The City of New York $124,359
- Ohsu Hospital and Clinics, OR $122,096
- Karmanos Cancer Center, MI $92,586
- Emory University Hospital, GA $62,807
- University of Miami $51,082
- Rutgers the State University $15,258
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.